Document Detail

Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
MedLine Citation:
PMID:  22104698     Owner:  NLM     Status:  MEDLINE    
AIMS: Pituitary prolactinoma is one of the estrogen-related tumors, some anti-estrogen compounds have suppressive effects on prolactinoma. Previous studies have suggested that resveratrol, a phytoestrogen, displays anti-estrogen and anti-tumor characteristics. Therefore, We determined whether resveratrol could inhibit the cell proliferation and decrease prolactin level in prolactinoma cell line, and identify the signaling pathways that mediate the effects of resveratrol.
MAIN METHODS: Prolactinoma cell line, GH3 cells were treated with resveratrol. Changes in proliferation, cell cycle, and apoptosis were assessed. The level of prolactin was assayed by Western blot or EIA. Expression of total Rb (retinoblastoma protein), phosphorylated Rb (pRb) and cyclin D3 were measured by Western blot. The changes of estrogen receptors and their roles in the effects of resveratrol were also determined.
KEY FINDINGS: We report that resveratrol had a dose-dependent inhibitory effect on GH3 cell proliferation. Inhibitory effects of resveratrol persisted, even on removal of resveratrol. The growth-inhibitory effect of resveratrol was accompanied by decreased expression of cyclin D3 and pRb. In addition, resveratrol induced G0/G1 cell cycle block and apoptosis. Furthermore, resveratrol suppressed intracellular levels and release of prolactin. Finally, we show that two types of estrogen receptor were involved in the different effects of resveratrol.
SIGNIFICANCE: Taken together, we demonstrate that resveratrol could inhibit prolactinoma cell proliferation, induce cell cycle block and apoptosis, and decrease prolactin production and release, and estrogen receptors mediate its antitumor effects. And thus, these results lead us to propose developing resveratrol as a novel therapeutic agent for treatment of prolactinoma.
Chao Wang; Zhi-qiang Hu; Ming Chu; Zhi Wang; Wei-guang Zhang; Lai-zang Wang; Chen-guang Li; Jun-sheng Wang
Related Documents :
9445378 - Capacity for repeatable leukotriene generation after transient stimulation of mast cell...
10768948 - Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargete...
9426208 - Functional lysophosphatidic acid receptor in bovine luteal cells.
3444378 - Metabolism of ether phospholipids and analogs in neoplastic cells.
17611058 - Hair cells in an ascidian (tunicata) and their evolution in chordates.
10781418 - Histamine alters endothelial barrier function at cell-cell and cell-matrix sites.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-11-21
Journal Detail:
Title:  Clinical neurology and neurosurgery     Volume:  114     ISSN:  1872-6968     ISO Abbreviation:  Clin Neurol Neurosurg     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-02     Completed Date:  2012-06-25     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  7502039     Medline TA:  Clin Neurol Neurosurg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  241-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Department of Neurosurgery, The Fourth Affiliated Hospital of Harbin Medical University, No. 37, YiYuan Street, NanGang District, Harbin 150001, Heilongjiang Province, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / pharmacology*
Apoptosis / drug effects
Blotting, Western
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Culture Media, Conditioned
Cyclin D3 / biosynthesis
Data Interpretation, Statistical
Dose-Response Relationship, Drug
Estrogen Receptor alpha / drug effects,  metabolism
Estrogen Receptor beta / drug effects,  metabolism
G0 Phase / drug effects
G1 Phase / drug effects
Indicators and Reagents
Microscopy, Electron, Transmission
Pituitary Neoplasms / drug therapy*,  metabolism*
Prolactin / metabolism*
Prolactinoma / drug therapy*,  metabolism*
Receptors, Estrogen / drug effects*
Stilbenes / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Culture Media, Conditioned; 0/Cyclin D3; 0/Estrogen Receptor alpha; 0/Estrogen Receptor beta; 0/Indicators and Reagents; 0/Receptors, Estrogen; 0/Stilbenes; 9002-62-4/Prolactin; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Usefulness of thallium-201 SPECT for prediction of early progression in low-grade astrocytomas diagn...
Next Document:  Interactions between hypoxia and sewage-derived contaminants on gene expression in fish embryos.